, a Canadian-based drug development and manufacturing firm, formally opened its newest facilities Wednesday at a headquarters and a lab facility in the Triangle.

The opening of what will serve as its U.S. headquarters was hardly the only news the company made this week, however.

Monday, a bidding war broke out for its stock, which is traded on the Toronto exchange under the symbol PTI.

Patheon, which announced plans in June to expand to North Carolina, is considering a takeover bid from JLL Partners, a U.S.-based private equity firm. JLL offered $2 a share, well above Patheon’s recent stock price.

JLL partners already owns 21 percent of Patheon, which makes drugs for other firms.

"We see this as a vote of confidence from JLL, as they are the largest shareholder in the company," Patheon spokesperson Jean Treadwell told Reuters.

Patheon plans to perform stability studies, validation testing and analytical chemistry services in its RTP lab.

The headquarters is located at the Imperial Center in RTP. The lab is in another building.

Patheon’s clients include more than 300 biotech and pharmaceutical firms.